Harvard Bioscience (HBIO) Cost of Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cost of Revenue data on file, last reported at $8.5 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $8.5 million, down 11.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 142.29% YoY), and the FY2025 annual result was $729000.0, down 98.15% from the prior year.
• Cost of Revenue improved to $8.5 million in Q1 2026 per HBIO's latest filing, from -$26.3 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $24.1 million in Q4 2023 and troughed at -$26.3 million in Q4 2025.
• A 5-year average of $7.6 million and a median of $9.4 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 133.96% in 2022, then slumped 216.83% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $12.6 million in 2022, then soared by 91.04% to $24.1 million in 2023, then slipped by 6.27% to $22.6 million in 2024, then tumbled by 216.83% to -$26.3 million in 2025, then jumped by 132.3% to $8.5 million in 2026.
• Business Quant data shows HBIO's Cost of Revenue at $8.5 million in Q1 2026, -$26.3 million in Q4 2025, and $48000.0 in Q3 2025.